-$0.58 EPS Expected for Scpharmaceuticals Inc (SCPH) This Quarter

Share on StockTwits

Wall Street brokerages expect Scpharmaceuticals Inc (NASDAQ:SCPH) to report ($0.58) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Scpharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.59). The firm is expected to report its next earnings results on Monday, August 6th.

According to Zacks, analysts expect that Scpharmaceuticals will report full-year earnings of ($2.22) per share for the current financial year, with EPS estimates ranging from ($2.35) to ($2.09). For the next year, analysts expect that the firm will post earnings of ($2.40) per share, with EPS estimates ranging from ($2.48) to ($2.31). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that follow Scpharmaceuticals.

Scpharmaceuticals (NASDAQ:SCPH) last released its earnings results on Monday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.04.

A number of brokerages recently weighed in on SCPH. Zacks Investment Research raised Scpharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 13th. Leerink Swann dropped their price objective on Scpharmaceuticals from $20.00 to $12.00 and set an “outperform” rating on the stock in a report on Thursday, June 14th. BMO Capital Markets dropped their price objective on Scpharmaceuticals from $24.00 to $14.00 and set an “outperform” rating on the stock in a report on Thursday, June 14th. ValuEngine raised Scpharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, Jefferies Financial Group dropped their price objective on Scpharmaceuticals from $26.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, June 14th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Scpharmaceuticals currently has an average rating of “Buy” and an average price target of $12.67.

Scpharmaceuticals traded down $0.36, reaching $5.53, on Thursday, Marketbeat reports. 299,600 shares of the company’s stock were exchanged, compared to its average volume of 111,203. Scpharmaceuticals has a twelve month low of $5.25 and a twelve month high of $18.17. The firm has a market capitalization of $112.18 million and a PE ratio of -0.66. The company has a debt-to-equity ratio of 0.10, a current ratio of 19.23 and a quick ratio of 19.23.

Institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System acquired a new stake in Scpharmaceuticals in the first quarter valued at $139,000. Schwab Charles Investment Management Inc. acquired a new stake in Scpharmaceuticals in the first quarter valued at $167,000. Monashee Investment Management LLC acquired a new stake in Scpharmaceuticals in the fourth quarter valued at $230,000. Bank of New York Mellon Corp acquired a new stake in Scpharmaceuticals in the fourth quarter valued at $414,000. Finally, Millennium Management LLC acquired a new stake in Scpharmaceuticals in the fourth quarter valued at $462,000. 44.87% of the stock is currently owned by institutional investors.

About Scpharmaceuticals

scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.

Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Scpharmaceuticals (NASDAQ:SCPH)

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply